Senestech(SNES.US)

Company Encyclopedia
View More
name
Senestech
SNES.US
SenesTech, Inc. engages in the development and commercialization of a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide and triptolide; and Evolve, a soft bait containing the active ingredient, cottonseed oil that limits the reproduction of male and female rats beginning with the first breeding cycles following consumption, as well as Evolve Mouse, a modified version of its bait technology containing the active ingredient cottonseed oil that limits reproduction of male and female mice after one to two breeding cycles following consumption. The company also provides teleconsulting and technical advisory services.
4.691 T
SNES.USMarket value -Rank by Market Cap -/-

Financial Score

01/01/2026 Update
C
PharmaceuticalsIndustry
Industry Ranking98/186
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-77.79%E
    • Profit Margin-253.54%E
    • Gross Margin62.75%A
  • Growth ScoreA
    • Revenue YoY39.37%A
    • Net Profit YoY12.43%C
    • Total Assets YoY228.70%A
    • Net Assets YoY210.82%A
  • Cash ScoreB
    • Cash Flow Margin-39.44%D
    • OCF YoY39.37%A
  • Operating ScoreD
    • Turnover0.24D
  • Debt ScoreA
    • Gearing Ratio22.40%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Review After SenesTech On-Site Factory Tour

    Mark Hake from TalkMarkets conducted a factory tour of SenesTech, assessing its operations, product differentiation, and business model. The focus was on SenesTech's Evolve rodent birth control product, which generates recurring revenue. The interview highlighted production scalability, international growth opportunities, and financial risks. Key milestones for achieving sustainable cash flow were discussed. The full interview is available, starting at the 16:30 mark.

    Talkmarkets·
    US
    SNES
    -0.93%
    Talkmarkets·
    US
    SNES
    -0.93%

    SenesTech's 43% Revenue Surge That Nobody’s Talking About

    SenesTech (SNES) reported a 43.2% YoY revenue increase in Q3, driven by its rat fertility-suppression product, Evolve. The company is expanding its e-commerce presence, selling on platforms like Lowes.com, Amazon, and Home Depot. With a market cap of $15 million and $10.2 million in cash, SenesTech aims for cash flow positivity. Evolve's effectiveness and international expansion, with approvals in 18 countries, are key growth drivers. Despite negative free cash flow, recurring sales potential and strong gross margins highlight significant upside for SNES stock.

    Talkmarkets·
    US
    SNES
    -0.93%
    Talkmarkets·
    US
    SNES
    -0.93%

    SenesTech Director Jacob Steven Leach Reports Sale of Common Shares

    Jacob Steven Leach, a Director at SenesTech Inc., reported the sale of common shares of the company. The filing is available via EDGAR, the SEC's system. This information is for informational purposes only and not financial advice.

    Reuters·
    US
    SNES
    -0.93%
    Reuters·
    US
    SNES
    -0.93%

    SenesTech Director Matthew K. Szot Reports Sale of Common Shares

    Matthew K. Szot, Director of SenesTech Inc., reported the sale of common shares of the company. The original filing is available via EDGAR, the SEC's system. This news is generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    SNES
    -0.93%
    Reuters·
    US
    SNES
    -0.93%

    SenesTech Generates Strong Revenue Growth - Huge Upside Possible

    SenesTech (SNES) reported a 43.2% YoY and 10.4% QoQ revenue increase in Q3, driven by its rat fertility-suppression product, Evolve. The company is expanding its e-commerce presence, including sales on Lowes.com, Amazon, and Home Depot. With a market cap of $15 million and $10.2 million in cash, SenesTech aims to become cash flow positive. The company sees significant growth potential in the $1 billion U.S. and $4.5 billion international rodent control markets, with Evolve offering a sustainable alternative to traditional rodenticides.

    Talkmarkets·
    US
    SNES
    -0.93%
    Talkmarkets·
    US
    SNES
    -0.93%
    © 2026 Longbridge｜Disclaimer